{
    "clinical_study": {
        "@rank": "131115", 
        "arm_group": [
            {
                "arm_group_label": "Elderly subjects aged over 60 years", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Adults from 18 to 60 years old inclusive", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is to assess whether the influenza vaccine Inflexal V for season 2013/2014\n      fulfills the EMA requirements for re-registration of influenza vaccines."
        }, 
        "brief_title": "Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female and male adults aged \u226518 on Day 1\n\n          -  Written informed consent\n\n          -  Female subjects of childbearing potential using and willing to continue using an\n             acceptable method of contraception unless surgically sterilized/hysterectomized or\n             post-menopausal for more than 2 years\n\n        Exclusion Criteria:\n\n          -  Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or\n             other acute disease\n\n          -  Acute febrile illness (\u226538.0 \u00b0C)\n\n          -  Prior vaccination with an influenza vaccine in the past 330 days\n\n          -  Known hypersensitivity to any vaccine component\n\n          -  Previous history of a serious adverse reaction to influenza vaccine\n\n          -  History of egg protein allergy or severe atopy\n\n          -  Known blood coagulation disorder\n\n          -  Chronic (longer than 14 days) administration of immunosuppressants or other\n             immune-modifying drugs within 6 months before the first dose of the study vaccine,\n             including oral corticosteroids in dosages of \u22650.5 mg/kg/d prednisolone or equivalent\n             (inhaled or topical steroids are allowed)\n\n          -  Known immunodeficiency (incl. leukemia, HIV seropositivity), cancer\n\n          -  Investigational medicinal product received in the past 3 months (90 days)\n\n          -  Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months\n             (90 days)\n\n          -  Pregnancy or lactation\n\n          -  Participation in another clinical trial\n\n          -  Employee at the investigational site, or relative of the investigator\n\n          -  Subjects who in the view of the investigator will not comply with study procedures\n             and/or visit requirements as per protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893177", 
            "org_study_id": "INF-V-A018"
        }, 
        "intervention": {
            "arm_group_label": [
                "Elderly subjects aged over 60 years", 
                "Adults from 18 to 60 years old inclusive"
            ], 
            "description": "Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V", 
            "intervention_name": "Inflexal V", 
            "intervention_type": "Biological", 
            "other_name": [
                "Inflexal V influenza vaccine (surface antigen, inactivated, virosome) formulated for the WHO requirements of the 2013-2014 season, each 0.5 mL dose containing:", 
                "\u2022 15 \u00b5g HA antigen of A/California/7/2009 (H1N1)-like virus", 
                "\u2022 15 \u00b5g HA antigen of A/Texas/50/2012 (H3N2)-like virus", 
                "\u2022 15 \u00b5g HA antigen of B/Massachusetts/2/2012-like virus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza", 
            "Virus", 
            "Vaccination", 
            "Inflexal V"
        ], 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Arzo", 
                    "country": "Switzerland", 
                    "zip": "6864"
                }, 
                "name": "CROSS Research S.A. - Phase I Unit"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2013/2014-season Virosomal Subunit Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations", 
        "overall_official": {
            "affiliation": "Cross Research S.A.", 
            "last_name": "Milko Radicioni, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Immunogenicity variables are analyzed according to the EMA re-licensing criteria; at least one of the criteria has to be fulfilled for each vaccine strain:\nSeroconversion rate at Day 22 has to be >40% of subjects aged \u226518 to \u226460 years and >30% of subjects aged >60 years, or\nSeroprotection rate at Day 22 has to be >70% of subjects aged \u226518 to \u226460 years and >60% of subjects aged >60 years, or\nGMT-fold increase at Day 22 compared to baseline: a >2.5-fold increase has to be reached in subjects aged \u226518 to \u226460 years and a >2.0-fold increase has to be reached in subjects aged >60 years", 
            "measure": "Percentage of subjects with seroconversion, seroprotection, and fold increase in geometric mean titer (GMT)", 
            "safety_issue": "No", 
            "time_frame": "Day 22 +/- 2 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893177"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of solicited local adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 to 4 inclusive"
            }, 
            {
                "measure": "Incidence of solicited systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 to 4 inclusive"
            }, 
            {
                "measure": "Incidence of unsolicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 to 22 inclusive"
            }
        ], 
        "source": "Crucell Holland BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Crucell Holland BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}